Clinical value and molecular role of PRDXs family in prostate cancer
Yong Yao, Quan Zheng, Chen Qian, Peng Gu, Minhao Zhang, Zhou Zhang · 2025
Read Clinical value and molecular role of PRDXs family in prostate cancer by Yong Yao, Quan Zheng, Chen Qian, Peng Gu, Minhao Zhang, Zhou Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722442.txt.
Description
Yong Yao and co-authors present a 2025 study of a family of proteins, called PRDXs, in prostate cancer. These proteins help cells deal with strain from oxygen, and their levels may shift as tumors grow. The team asked whether the six members of the family could help doctors spot the disease or judge how it will go.
Using a large cancer database, the team found two members at high levels in prostate tumors. Lab tests on cancer cells and tissue samples backed the pattern. One member, PRDX4, stood out as the most useful marker. When the team silenced PRDX4 in cancer cells, the cells grew and spread less. The study also maps proteins that work with PRDX4 and lists plant-based drugs that might target it. The work points to a fresh lead for tests and care.
Catalog record
| CREATOR | Yong Yao, Quan Zheng, Chen Qian, Peng Gu, Minhao Zhang, Zhou Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |